Stem Cell Therapy for Multiple Sclerosis: Science, Evidence, and your Options
Multiple sclerosis (MS) is one of the most common neurological conditions in young adults, affecting approximately 2.9 million people worldwide. It is an autoimmune disease in which the immune system attacks myelin - the protective sheath around nerve fibres - causing progressive neurological damage that accumulates over time.
Stem cell therapy represents one of the most actively researched frontiers in MS treatment, and the evidence base has grown substantially in recent years.
Understanding the Different Types of MS
Treatment response to any therapy - conventional or regenerative - depends significantly on which form of MS you have:
Relapsing-Remitting MS (RRMS) - The most common form (85% of diagnoses). Characterised by distinct episodes of neurological worsening followed by partial or full recovery. Active inflammation drives the relapses.
Secondary Progressive MS (SPMS) - Develops in many RRMS patients over time. Neurological decline becomes gradual and continuous, with fewer distinct relapses but accumulating disability.
Primary Progressive MS (PPMS) - Begins with steady progression from onset, without clear relapses. Harder to treat, but recent research shows promise.
Two Different Stem Cell Approaches - Understanding the Distinction
Two fundamentally different stem cell strategies are being investigated for MS, and they are often confused:
Haematopoietic Stem Cell Transplantation (HSCT) essentially "reboots" the immune system by destroying it with chemotherapy and rebuilding it from haematopoietic stem cells. It is the most aggressive approach, with strong evidence for halting RRMS in younger patients with highly active disease. It involves significant short-term risks and is appropriate only for a carefully selected minority.
Mesenchymal Stem Cell (MSC) Therapy is an entirely different, far less aggressive approach. MSCs do not destroy the immune system. Instead, they modulate it - suppressing the overactive inflammatory T-cell response that drives myelin damage. They also secrete neurotrophic factors that support remyelination and protect surviving neurons. A 2025 review published in PubMed concludes that "MSC therapy holds potential for slowing disease progression and promoting neurological recovery in MS patients."
Medical Cells Network advises exclusively on MSC-based and pluripotent allogeneic protocols. We do not advise on HSCT.
What Does the Clinical Evidence Show?
The evidence base for MSC therapy in MS is building steadily. Key findings from recent research include:
- A Phase 2 trial of adipose-derived MSC therapy presented at ECTRIMS 2025 met its primary endpoint in relapsing-remitting MS, demonstrating both safety and efficacy.
- A safety and feasibility study using placenta-derived MSCs in secondary-progressive MS patients, published in Nature Scientific Reports, confirmed tolerability with preliminary efficacy signals.
- Frontiers in Cell and Developmental Biology (2025) documents a trend toward reduced inflammatory markers and stabilised lesion activity in RRMS patients treated with MSCs.
Across multiple trials, patients have reported improvements in fatigue (one of the most debilitating MS symptoms), reduced spasticity, modest improvements in mobility, and stabilisation of disease markers on MRI.
What Outcomes Are Realistic?
For patients with active relapsing disease or early progressive MS with detectable inflammation, the most evidence-supported outcomes are:
- Slowing or stabilisation of progression
- Reduction in relapse frequency
- Improved fatigue levels and quality of life
- Reduced inflammatory activity on MRI scans
For advanced progressive MS, the evidence is less robust - but neuroinflammation is present throughout the disease course, and some patients with progressive forms have also responded. Individual assessment is essential.
How We Can Help
Our advisory process begins with a detailed review of your most recent MRI reports, neurological assessments, and treatment history. We then identify whether your profile aligns with published protocols that have shown benefit, and which GMP-certified clinical partners in Germany, Switzerland, or Georgia would be best suited to your needs.
We also help you evaluate how stem cell therapy might complement - not replace - your current disease-modifying treatment.
Frequently Asked Questions - Stem Cells and MS
Is MSC therapy the same as the stem cell transplant I've read about for MS?
No. MSC therapy and HSCT (haematopoietic stem cell transplantation) are completely different. HSCT involves chemotherapy to destroy and rebuild the immune system - it is aggressive and suitable only for specific patients. MSC therapy is a far gentler immunomodulatory approach.
Can stem cell therapy work if I have had MS for many years?
Longer disease duration reduces but does not eliminate potential benefit. The key factor is whether active neuroinflammation is still present - which it typically is even in progressive forms. Our advisory assessment will help determine your individual likelihood of response.
Will I need to stop my current MS medications?
This depends on the specific protocol and your current treatment. Some medications may interact with cell therapy preparation. We will review your current regimen as part of the advisory process and coordinate with your treating neurologist.
How is it administered?
MSC protocols for MS are typically administered intravenously (IV), sometimes combined with intrathecal injection (directly into the spinal fluid) for enhanced CNS access.